(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dilated cardiomyopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Dilated cardiomyopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Dilated cardiomyopathy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dilated cardiomyopathy Market.
The Dilated cardiomyopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Dilated cardiomyopathy Pipeline Report:
- Companies across the globe are diligently working toward developing novel Dilated cardiomyopathy treatment therapies with a considerable amount of success over the years.
- Dilated cardiomyopathy companies working in the treatment market are Squibb, Berlin Cures, Pfizer, Bristol-Mayers Squibb, Capricor Therapeutics, Cumberland Pharmaceuticals, and others, are developing therapies for the Dilated cardiomyopathy treatment
- Emerging Dilated cardiomyopathy therapies such as – AVB-401, DINA-006, HS-001, Danicamtiv, BC 007, PF-07265803, ARRY-371797, MYK-491, CAP-1002, Ifetroban, and others are expected to have a significant impact on the Dilated cardiomyopathy market in the coming years.
- In November 2020, Bristol Myers Squibb announced that it has successfully completed its acquisition of MyoKardia,Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb
Dilated cardiomyopathy Overview
Dilated cardiomyopathy (DCM) is the most common type, occurring mostly in adults younger than 50. It primarily affects the heart’s ventricles and atria, the lower and upper chambers of the heart. It is a non-ischaemic heart muscle disease with structural and functional myocardial abnormalities.
Get a Free Sample PDF Report to know more about Dilated cardiomyopathy Pipeline Therapeutic Assessment
Emerging Dilated cardiomyopathy Drugs Under Different Phases of Clinical Development Include:
- AVB-401: Solid Biosciences Inc.
- DINA-006: DiNAQOR
- HS-001: Heartseed
- Danicamtiv: MyoKardia
- Ixmyelocel-T: Vericel
- Danicamtiv: Bristol-Myers Squibb
- BC 007: Berlin Cures
Route of Administration
Dilated cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
- Small molecule
- Cell Therapy
- Small molecule
- Gene therapy
Dilated cardiomyopathy Pipeline Therapeutics Assessment
- Dilated cardiomyopathy Assessment by Product Type
- Dilated cardiomyopathy By Stage and Product Type
- Dilated cardiomyopathy Assessment by Route of Administration
- Dilated cardiomyopathy By Stage and Route of Administration
- Dilated cardiomyopathy Assessment by Molecule Type
- Dilated cardiomyopathy by Stage and Molecule Type
DelveInsight’s Dilated cardiomyopathy Report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Dilated cardiomyopathy product details are provided in the report. Download the Dilated cardiomyopathy pipeline report to learn more about the emerging Dilated cardiomyopathy therapies
Some of the key companies in the Dilated cardiomyopathy Therapeutics Market include:
Key companies developing therapies for Dilated cardiomyopathy are – DiNAQOR AG, Renovacor Inc, Bristol-Myers Squibb Co, Tenaya Therapeutics Inc, Avery Therapeutics Inc, Berlin Cures Holding AG, BioMarin Pharmaceutical Inc, BridgeBio Pharma Inc, Cardior Pharmaceuticals GmbH, Celixir Ltd., and others.
Dilated cardiomyopathy Pipeline Analysis:
The Dilated cardiomyopathy pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Dilated cardiomyopathy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dilated cardiomyopathy Treatment.
- Dilated cardiomyopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Dilated cardiomyopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dilated cardiomyopathy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Dilated cardiomyopathy drugs and therapies
Dilated cardiomyopathy Pipeline Market Drivers
- Need of novel treatment, rising incidence of congestive heart failure are some of the important factors that are fueling the Dilated cardiomyopathy Market.
Dilated cardiomyopathy Pipeline Market Barriers
- However, lack of pipeline therapies, several associated causes of Dilated cardiomyopathy and other factors are creating obstacles in the Dilated cardiomyopathy Market growth.
Scope of Dilated cardiomyopathy Pipeline Drug Insight
- Coverage: Global
- Key Dilated cardiomyopathy Companies: Squibb, Berlin Cures, Pfizer, Bristol-Mayers Squibb, Capricor Therapeutics, Cumberland Pharmaceuticals, and others
- Key Dilated cardiomyopathy Therapies: AVB-401, DINA-006, HS-001, Danicamtiv, BC 007, PF-07265803, ARRY-371797, MYK-491, CAP-1002, Ifetroban, and others
- Dilated cardiomyopathy Therapeutic Assessment: Dilated cardiomyopathy current marketed and Dilated cardiomyopathy emerging therapies
- Dilated cardiomyopathy Market Dynamics: Dilated cardiomyopathy market drivers and Dilated cardiomyopathy market barriers
Request for Sample PDF Report for Dilated cardiomyopathy Pipeline Assessment and clinical trials
Table of Contents
|1||Dilated cardiomyopathy Report Introduction|
|2||Dilated cardiomyopathy Executive Summary|
|3||Dilated cardiomyopathy Overview|
|4||Dilated cardiomyopathy- Analytical Perspective In-depth Commercial Assessment|
|5||Dilated cardiomyopathy Pipeline Therapeutics|
|6||Dilated cardiomyopathy Late Stage Products (Phase II/III)|
|7||Dilated cardiomyopathy Mid Stage Products (Phase II)|
|8||Dilated cardiomyopathy Early Stage Products (Phase I)|
|9||Dilated cardiomyopathy Preclinical Stage Products|
|10||Dilated cardiomyopathy Therapeutics Assessment|
|11||Dilated cardiomyopathy Inactive Products|
|12||Company-University Collaborations (Licensing/Partnering) Analysis|
|13||Dilated cardiomyopathy Companies|
|14||Dilated cardiomyopathy Products|
|15||Dilated cardiomyopathy Unmet Needs|
|16||Dilated cardiomyopathy Market Drivers and Barriers|
|17||Dilated cardiomyopathy Future Perspectives and Conclusion|
|18||Dilated cardiomyopathy Analyst Views|
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
DelveInsight’s ‘Dilated cardiomyopathy-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Dilated cardiomyopathy Epidemiology
DelveInsight’s ‘Dilated cardiomyopathy Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight’s “Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Vein Illumination Devices Market
DelveInsight’s “Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
DelveInsight’s “Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Related Reports by DelveInsight-
Scedosporium Infection Market | Autoimmune Pulmonary Alveolar Proteinosis Market | Rosai-Dorfman Disease Market | Sandhoff Disease Market | B-Cell Chronic Lymphocytic Leukemia Market | Bladder Cancer Market | Trichomoniasis Market | Bile Duct Cancer Market | Resorbable Vascular Scaffold Market | Salivary Gland Infection Market | Ischemic Stroke Market | Paget’s Disease Market | Ventricular Assist Devices Market | Vascular Stents Market | Vascular Graft Devices Market | Bladder Scanners Market | B-Cell Non-Hodgkin Lymphoma Market | Basal Cell Carcinoma Market | Birch Allergy Market | Vein Illumination Devices Market
- Hip Replacement Devices Market
- Age Related Vision Dysfunction Market
- Interbody Cages Market
- Hpv-Induced Cancers Market
- Wilms Tumor Market
- Cardiorenal Syndrome Market
- Capnography Device Market
- Contraceptive Devices Market
- Global Electrophysiology Devices Market
Recent Blog’s By DelveInsight:
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
- Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.